HST Global, Inc. Announces New Board Member
Posted on: Friday, 11 July 2008, 09:01 CDT
HST Global, Inc. (OTCBB: HSTC), a development stage biotechnology company, today announced the appointment of Dr. James W. Forsythe to their Board of Directors. Dr. Forsythe brings over thirty years of medical and research experience to complement the business background of current board members.
"Dr. Forsythe's strong ties to the medical and research community will be a valuable asset to our board," said Ron Howell, CEO and President of HST Global, Inc. "James will be instrumental in helping us increase our visibility of new technology and research applications." Currently, Dr. Forsythe is an Associate Professor of Medicine and Pathology, University of Nevada Medical School Reno, NV. Prior to that, he was an instructor in Medicine and Hematology, University of California Medical Center, San Francisco, CA.
Dr. Forsythe received his Doctorate of Medicine from the University of California, San Francisco and his Undergraduate Degree from University of California at Berkeley. Dr. Forsythe is certified in Homeopathy and Board Certified in Internal Medicine, Medical Oncology and Utilization Review and Quality Assurance. He is also Board eligible in Clinical Pathology and Medical Gerontology. Dr. Forsythe is also the owner and Medical Director of Cancer Screening and Treatment Center of Nevada and Century Wellness Clinic. In addition, Dr. Forsythe spent 26 years in the United States Army Medical Corps, retiring full Colonel. He was also the former State Surgeon in the Nevada Army National Guard.
About HST Global, Inc.
HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.
Source: Business Wire
Related Articles
- EMD Serono, Inc. and The University of Texas M. D. Anderson Cancer Center Announce Collaboration for Preclinical Research, Clinical Trials
- HST Global, Inc. Sets New Standards in the Treatment of Stage IV Breast Cancer!
- Lighting the Onco-Pipeline, Stem Cell Cancer, and More at Global Cancer Congress, January 28-29, 2008, Tampa
- Rosetta Genomics Signs Research Agreement With Columbia University Medical Center to Advance Its Lead Cancer Diagnostics Program
- OHSU Cancer Institute Researcher Identifies Protein Marker for Prostate Cancer Survival
- The University of New Mexico Cancer Center, New Mexico's Official Cancer Center, Opens a New Facility in Las Cruces
- TyRx Pharma, Inc., Announces the Signing of Exclusive License Agreement With Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center
- Medical Board Suspends Cancer Doctor's License
- Targeted Molecular Diagnostics Announces New Collaboration With Researchers at University of Texas M.D. Anderson Cancer Center
 |
 |
User Comments (0)
RSS Feeds